Cytokine Release Syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction that is associated with chimeric antigen receptor (CAR)-T cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation.
Epidemiology Segmentation in 7MM from 2017 to 2030
Epidemiology Insights
Scope of Cytokine Release Syndrome Report
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Cytokine Release Syndrome (CRS)
3. Disease Background and Overview: Cytokine Release Syndrome (CRS)
3.1. Introduction
3.2. Symptoms
3.3. Causes
3.4. Risk Factors
3.5. Pathophysiology
3.6. Biomarkers
3.7. CRS in patients with COVID-19 infection
3.8. Diagnosis
3.8.1. Grading
4. Case Reports
4.1. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: A case report
4.2. The first case of cytokine release syndrome after nivolumab for gastric cancer
4.3. Multimodal therapeutic approach of Cytokine Release Syndrome developing in a child given chimeric antigen receptor-modified T-cell Infusion
5. Cytokine Release Syndrome Epidemiology and Patient Population
5.1. Key Findings
5.2. Scope
5.3. KOL Views
5.4. Multiple Myeloma Treatment Paradigm
5.5. DLBCL Treatment Paradigm
5.6. ALL Treatment Paradigm
5.7. CAR-T Cell Therapies Forecast Flow
5.8. CRS Epidemiology Methodology
5.9. Total Number of Hematologic Malignancies Patients receiving CAR-T Cell Therapies in the 7MM
5.10. Total Number of Patients develop CRS following CAR-T Cell Therapies in the 7MM
6. United States Epidemiology
6.1. Assumptions and Rationale
6.2. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the United States
6.3. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in the United States
6.4. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in the United States
6.5. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in the United States
6.6. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in the United States
7. EU5 Epidemiology
7.1. Assumptions and Rationale
7.2. Germany Epidemiology
7.2.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Germany
7.2.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Germany
7.2.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Germany
7.2.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Germany
7.2.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Germany
7.3. France Epidemiology
7.3.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in France
7.3.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in France
7.3.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in France
7.3.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in France
7.3.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in France
7.4. Italy Epidemiology
7.4.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Italy
7.4.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Italy
7.4.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Italy
7.4.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Italy
7.4.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Italy
7.5. Spain Epidemiology
7.5.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Spain
7.5.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Spain
7.5.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Spain
7.5.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Spain
7.5.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Spain
7.6. United Kingdom Epidemiology
7.6.1. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in the UK
7.6.2. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in the UK
7.6.3. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in the UK
7.6.4. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in the UK
7.6.5. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in the United Kingdom
8. Japan Epidemiology
8.1. Assumptions and Rationale
8.2. Total Number of B-cell NHL Patients receiving CAR-T Cell Therapies in Japan
8.3. Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies in Japan
8.4. Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies in Japan
8.5. Total Number of Patients developing Cytokine Release Syndrome (CRS) following CAR-T Cell Therapies in Japan
8.6. Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade in Japan
9. Appendix
9.1. Bibliography
9.2. Cytokine Release Syndrome Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: DelveInsightEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/